Attorney Grant Hollingsworth outlines Trump administration changes that could positively or negatively affect a preemption defense in drug and medical device litigation.
CDER acting director Tracy Beth Hoeg says the Center is preparing new safety reviews of widely used antidepressants and monoclonal antibodies for respiratory syncytial virus.
Attorney Grant Hollingsworth outlines Trump administration changes that could positively or negatively affect a preemption defense in drug and medical device litigation.
CDER acting director Tracy Beth Hoeg says the Center is preparing new safety reviews of widely used antidepressants and monoclonal antibodies for respiratory syncytial virus.
FDA cites significant data integrity and quality control failures at an Indian manufacturing facility operated by Aurobindo Pharma that was inspected earlier in the month.
A Maryland federal judge dismisses a physician’s bid to force FDA to create a special, conditional access pathway for certain experimental Alzheimer’s treatments.
